Complications of Transcutaneous Protheses – A Systematic Review of Publications Over the Past 10 Years

Marcos Antonio de Souza1 Santiago Luis Vallejos Riart2 Stephanie Rugeri de Souza1 Rubens de Brito1 Ricardo Ferreira Bento1

1 Department of Otorhinolaryngology, Universidade de São Paulo (USP), São Paulo, SP, Brazil
2 Department of Otorhinolaryngology, Universidad Nacional de Asunción (UNA), San Lorenzo, Central, Paraguay

Address for correspondence Marcos Antonio de Souza, MD, Departamento de Otorrinolaringología, USP, Av. Dr. Enéas Carvalho de Aguiar, 255 - Cerqueira César, São Paulo, SP 05403-000, Brazil (e-mail: marcosantonio.med@gmail.com).

Abstract

Introduction Bone conduction implants, responsible for transmitting sound from an external processor to the inner ear, can be divided into active and passive, depending on the vibratory stimulus location. The use of transcutaneous device has increased, given its aesthetic appeal, the complications and limitations of percutaneous devices, and patient’s treatment adherence, focusing mainly on efficacy. However, various complications are associated with the use of transcutaneous prosthesis, which can often be serious.

Objective To approach the literature on complications involving transcutaneous bone-anchored protheses through a systematic review of articles published in the past 10 years (2011–2021).

Data Synthesis The MEDLINE, EMBASE, Scopus, and Cochrane Library databases were searched. All articles written in English reporting on currently available transcutaneous prosthesis implantation and its complications were selected. Studies on both children and adults were included. The data on complications were extracted, and complications were classified as minor or major and associated to each device used. Thirty-seven articles were included in the study, of which 14 were prospective cohort studies, 22 were retrospective case series, and 1 was a case report. Most studies (18) included both adults and children. Moreover, 901 implantations were performed, of which 552 implanted Baha Attract (Cochlear Ltd., Sydney, Australia), 244 implanted BoneBridge (MED-EL, Innsbruck, Austria), and 105 implanted Sophono (Sophono Inc., Boulder, CO, USA). Furthermore, 192 adverse events were reported (total complication rate, 21.3%), with 161 minor complications (84.3%) and 31 major complications (16.1%).

Conclusion Transcutaneous prosthesis is an audiological alternative with fewer complications than percutaneous prosthesis. However, its indication should be judicious because complications are common, and although most complications are minor, serious infections requiring explantation may develop.
Introduction

The conduction of sound through bone was already known in the 2nd century AD by Claudius Galenus (131–200) and was first described and applied by Girolamo Cardano (1510–1580). Following this principle, Ludwig van Beethoven (1770–1827), with an advanced hearing loss in his last years, used a stick with one end resting on his piano and the other between his teeth to transmit sound to his ears.

Bone-conduction implants transmit auditory stimuli from an external audio processor to the inner ear. Hearing is produced by conducting sound waves through the skull bones to the cochlea, bypassing the outer and middle ears. These devices have been shown to effectively treat conductive and mixed hearing loss and unilateral deafness. They are a better treatment option than reconstructive surgery for patients with bilateral aural atresia, presenting great advantages in terms of audiological outcomes and complications.

Currently, bone-conduction devices available on the market can be classified into two main categories: percutaneous devices, which penetrate the skin and have a direct connection to the implant (Baha Connect [Cochlear Bone-Anchored Solutions AB, Mölnlycke, Sweden] and Ponto [Oticon Medical AB, Askim, Sweden]), and transcutaneous devices, which communicate with the implant through intact skin and are held together by magnets. Transcutaneous devices, in turn, are divided into passive bone-conduction systems, in which vibration is transmitted from the processor to the implant through the skin using a magnet (BoneBridge [MED-EL, Innsbruck, Austria] and Osia [Cochlear Ltd., Sydney, Australia]), and active systems, in which the implant directly generates vibration and applies it to the bone (Baha Connect [MED-EL, Innsbruck, Austria] and Osia [Cochlear Ltd., Sydney, Australia]).

Percutaneous implants have been well studied and have excellent audiological results. However, many patients prefer not to undergo this surgery for aesthetic reasons related to the percutaneous abutment or due to possible complications, such as infection, skin overgrowth at the external site of the implant, and skin rupture or necrosis, which can lead to loss of implant.

In the last decade, the use of transcutaneous devices has increased, given the complications and limitations of percutaneous devices, in addition to the aesthetic appeal associated with transcutaneous prostheses and patient adherence to treatment, focusing mainly on efficacy. These benefits are also supported by studies that suggest that fewer complications occur with transcutaneous models than with percutaneous ones. However, hearing results still have worse performance due to sound cushioning through the skin.

The present study aims to systematically review the articles published in the past 10 years and listed in the available databases presenting patients with transcutaneous bone-conduction devices and the complications associated with these devices to document these lesions and assist in the selection of these devices.

Review of Literature

The present study includes a systematic review of the postoperative complications related to transcutaneous bone-anchored prostheses, through an analysis of articles addressing this topic that were published in the past 10 years (2011–2021).

Search Methodology

Our institution’s health sciences research librarian was consulted, and a structured query was performed in May 2021. The analyzed databases were PUBMED, EMBASE, Cochrane Library, LILACS, SCOPUS, and Web of Science.

The query terms, with their respective combinations, were hearing aid OR bone conduction OR transcutaneous AND complications (Baha Attract OR Sophono OR BoneBridge) AND bone conduction implant OR bone-conduction implant, with filters applied for publications from the previous 10 years and for study design.

The query results for each database were compiled, and, initially, duplicate articles were identified and removed. All abstracts were reviewed by two authors (M. A. S. and S. L. V.) regarding their relevance and alignment with the subject under study.

The full text of the relevant studies was reviewed, and the reference lists were cross-checked to identify important additional studies. Disagreement regarding the inclusion of individual studies was resolved after a debate between the two reviewers.

Inclusion Criteria

The inclusion criteria consisted of articles published only in English, addressing the implantation of active and passive transcutaneous prostheses (BoneBridge, Sophono, or Baha Attract) and the complications derived from the implantation. The reason for choosing these specific implants relates to the vast literature available about them, given the time they already have been on the market. Implants that were launched in the previous 5 years, on average, and those with only sporadic use or lacking more scientific evidence were excluded. Studies with both adult and pediatric populations were selected.

All selected studies had their abstracts read in full, and those that addressed the performance of a transcutaneous prosthesis, the existence of complications related to the prosthesis, and studied a human population were selected for full-text reading. Studies that exclusively addressed percutaneous prostheses, cochlear implants, and prostheses, and those that did not delimit possible complications were excluded. There was no limitation on the level of evidence.

After reading the articles selected in full, the two authors rated the complications. Complications were considered to be major when they required active medical or surgical treatment, such as new surgical procedures, or when their existence led to the cessation of use of the device. Minor complications consisted of minor soft-tissue reactions, including pain and erythema, that may have reduced the use of
the device, but did not prevent that use altogether. Such complications were necessarily corrected only with conservative measures.

The exclusion criteria comprised articles that were not available in English, those based on laboratory or cadaver models, 3D reproductions, review articles without additional patients reported, and articles reporting preliminary results for later publications that described the same cohort of patients. Articles that addressed transcutaneous prostheses but had no reports of complications were also excluded.

Study Selection

The delimited query strategy yielded 274 articles (Fig. 1). After filtering out duplicate articles, 231 articles remained for review and abstract reading. Based on the analysis of the abstracts, 93 articles were selected for full-text reading and analysis, of which 56 were excluded for the following reasons: 26 did not define in their text the occurrence of complications, either minor or major, or were only descriptive reports published as book chapters; 13 addressed the occurrence of complications of percutaneous or other prostheses that were not included in the present study design; 6 articles were systematic reviews that did not add additional patients; 8 articles were not available in English; and 3 were abstracts without an associated published manuscript. The 37 selected articles are available in Table 1.

The included studies comprised 14 prospective cohort studies, 22 retrospective case series, and 1 case report. Most studies (18) included both adult and pediatric patients, while

![Fig. 1 Systematic review.](image)
| Author          | Demographic population | Study type          | Device       | n (number of implants) | Description of the complications |
|-----------------|-------------------------|---------------------|--------------|------------------------|----------------------------------|
| Souza et al.    | Pediatric               | Retrospective case series | BoneBridge | 1                       | Emphysema adjacent to the implant |
| Sikolova (2021) | Pediatric               | Case report         | BoneBridge  | 1                       | Emphysema adjacent to the implant |
| Seiwerth (2021) | Adult and pediatric     | Retrospective case series | BoneBridge | 31                      | Skin redness                       |
| Hernandez (2021)| Pediatric               | Retrospective case series | BoneBridge | 4                       | Pain without infection            |
| Kryp (2020)     | Pediatric               | Retrospective case series | BoneBridge | 4                       | Pain without infection            |
| Bak (2020)      | Pediatric               | Case report         | BoneBridge  | 54                      | Pain without infection            |
| Chan (2019)     | Adult and pediatric     | Prospective cohort  | BoneBridge  | 10                      | Pain without infection            |
| Der (2018)      | Pediatric               | Retrospective case series | BoneBridge | 24                      | Pain without infection            |
| Reddy-Kolanu (2016)| Adult and pediatric | Prospective cohort  | BoneBridge  | 24                      | Pain without infection            |

Table 1 Summary of articles included with the complications reported
| Author          | Demographic population | Study type               | Device     | n (number of implants) | Complications | Description of the complications                                                                                                                                 |
|-----------------|-------------------------|--------------------------|------------|------------------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Shin (2016)     | Adult and pediatric     | Retrospective case series| Sophono    | 9                      | 2             | 1 - Local wound infection requiring explantation 2 - Pain/discomfort                                                                                      |
| Eberhard (2016) | Adult                   | Prospective cohort       | BoneBridge | 12                     | 1             | 1 - Surgical wound infection                                                                                                                                 |
| Marsella (2015) | Adult and pediatric     | Retrospective case series| Baha Attract| 3                      | 1             | 1 - Surgical wound infection                                                                                                                                 |
| Hassepass (2015)| Pediatric               | Retrospective case series| BoneBridge | 3                      | 1             | 1 - Hematoma                                                                                                                                               |
| O’Neill (2014)  | Pediatric               | Retrospective case series| Sophono    | 14                     | 4             | 1 - Redness/punctiform ulcer 1 - Skin necrosis due to pressure 2 - Pain 1 - Cellulitis with local infection and explantation                                      |
| Marsella (2014) | Pediatric               | Retrospective case series| Sophono    | 6                      | 0             | 1 - Ulceration of the skin 1 - Pain and hyperemia                                                                                                       |
| Ihler (2014)    | Pediatric               | Retrospective case series| Sophono    | 5                      | 2             | 1 - Surgical wound infection 1 - Discomfort on pressure                                                                                                   |
| Denoyelle (2013)| Pediatric               | Prospective cohort       | BoneBridge | 6                      | 0             | 1 - Prolonged wound healing.                                                                                                                                |
| Sylvester (2013)| Adult and pediatric     | Retrospective case series| Sophono    | 20                     | 2             | 1 - Skin erythema 1 - Irritation                                                                                                                              |
| Dolhen (2020)   | Adult and pediatric     | Prospective cohort       | Baha Attract| 10                     | 1             | 1 - Skin erythema                                                                                                                                             |
| Atshakh (2019)  | Adult and pediatric     | Retrospective case series| Baha Attract| 20                     | 2             | 1 - Numbness 1 - Mild discomfort                                                                                                                           |
| Hougaard (2017)| Adult and pediatric     | Prospective cohort       | Baha Attract| 20                     | 0             | 1 - Difficulty adjusting the processor                                                                                                                      |
| Zernotti (2016)| Adult and pediatric     | Retrospective case series| Baha Attract| 10                     | 1             | 1 - Mild pain in the wound                                                                                                                                   |
| Briggs (2015)   | Adult                   | Prospective, multicenter cohort| Baha Attract| 27                     | 9             | 62.9% - Numbness 4 - Erythema 4 - Pain 1 - Discomfort                                                                                                      |
| Iseri (2015)    | Adult and pediatric     | Retrospective, multicenter case series | Sophono    | 16                     | 4             | 1 - Skin erythema and pain 3 - Pain                                                                                                                                 |
| Denoyelle (2015)| Pediatric               | Prospective cohort       | Sophono    | 15                     | 7             | 2 - Skin erythema 2 - Hair loss 3 Brief episodes of pain or tingling                                                                                         |
| Dimitriadis (2017)| Adult and pediatric    | Prospective cohort       | Baha Attract| 105                    | 21            | 17 numbness of the skin 4 skin sensitivity and redness 2 skin break/rupture                                                                               |
| Baker (2015)    | Pediatric               | Retrospective case series| Baha Attract| 6                      | 0             | 1 - Surgical wound infection 1 - Headache requiring explantation                                                                                           |
12 studies focused specifically on children, and in 7 studies only adults were included.

**Results of the Integrative Review**

In the 37 articles included in the research, a total of 901 implantations were performed, of which 552 implanted Baha Attract devices, 244 implanted Bone Bridge, and 105 implanted Sophono. Regarding the type of implant reported, of the 37 articles under study, 14 reported exclusively on Baha Attract, 12 exclusively on BoneBridge, 8 exclusively on Sophono, and 3 articles addressed more than 1 type of prosthesis, including two reporting on both Baha Attract and Sophono, and one reporting on both BoneBridge and Sophono.

A total of 192 adverse events were reported, corresponding to a total complication rate of 21.3%. Four (2%) of these complications were due to either device malfunction or difficulty in adjusting the processor, and 188 (98%) were associated with injuries to the patient directly or indirectly associated with the implant. Most complications in absolute terms occurred with the use of Baha Attract (n = 135, 70.3%), but this was also the most used device in the series. However, taking into account the total complication rates, the device with the highest percentage of complications was Sophono (26.6%), followed by the Baha Attract (24.4%) and BoneBridge (11.8%). This same distribution was observed when considering the rates of minor complications specific to each type of implant (Sophono 22.8%, Baha Attract 22.1%, BoneBridge 6.1%), but it was not observed when considering the rates of major complications specific to each type of implant (BoneBridge 5.7%, Sophono 3.8%, Baha Attract 2.3%). Table 1 describes the adverse events reported by device type. All reports of adverse events occurred in postoperative settings.

The most commonly reported adverse events were minor complications (N = 161), which corresponded to 84.3% of all complications and a rate of 17.8%. These complications included mild pain, hyperemia, numbness, mild wound infection, and mild ulceration. None of these complications prevented the use of the hearing implant permanently, and all were resolved by reducing the strength of the magnet or decreasing the number of hours using the device per day, or even with local care.

Major complications (N = 31) were 16.1% of all complications. Their rate corresponded to 3.4% in the present series. Among these complications, the most frequent were wound infection or inflammation (N = 8, 25.8%), skin necrosis, ulceration, or prolonged healing (N = 6, 19.3%), and skin rupture (N = 5, 16.1%). The remaining complications were grouped in Table 2. All patients (100%) who had major complications had to stop using the hearing implant.

**Discussion**

Transcutaneous bone-conduction devices emerged as an alternative to percutaneous devices, because they do not require an abutment crossing the skin to support the external processor and, therefore, have advantages from an aesthetic point of view and regarding skin-related complications. Among the transcutaneous devices, active devices have an advantage over passive ones, as they require a lower-strength magnet to support themselves, and they also prevent the attenuation of vibrations produced by soft tissues. The aim of the present study is to document the complications associated with transcutaneous bone-conduction devices to assess the best treatment option for the patients.

The present review also showed that passive transcutaneous devices have higher complication rates than the active ones (Sophono 26.6% and Baha Attract 24.4% versus BoneBridge 11.8%). Some studies suggest that the complication rate for transcutaneous devices is around 35.7% for passive devices and 9.4% for active ones.

The rate of minor complications was 17.8%, with device-specific rates of 22.8% for Sophono, 22.1% for Baha Attract, and 6.1% for BoneBridge. This is in agreement with the literature, which reports that BoneBridge offers a lower rate of complications, especially when compared with percutaneous prostheses.

With regard to the treatment of situations such as minor complications (hyperemia, skin edema, mild infection, pain), treatment was generally and predominantly clinical, progressing with local care and systemic oral antibiotic therapy. These complications were linked to, at most, momentary discontinuation of implant use, and more aggressive conduct, such as explantations, were not required. According to Kruyt (2020) and Gawel (2019), in a prospective cohort in which Baha Attract was used, it was evidenced that most patients initially reported experiencing some degree of pain or discomfort and numbness. However, these complication rates decreased during follow-up, being reported only sporadically in the last follow-up consultation.

**Table 2 Summary of complications**

| Major complications                                      | N |
|----------------------------------------------------------|---|
| Seroma/hematoma                                          | 1 |
| Surgical wound infections/explantation                   | 8 |
| Skin rupture                                             | 5 |
| Difficulty adjusting processor                           | 2 |
| Device fault                                             | 2 |
| Necrosis/skin ulceration/prolonged healing               | 6 |
| Extrusion                                                | 2 |
| Compressive symptoms                                     | 1 |
| Refractory headache                                       | 1 |
| Tinnitus                                                 | 1 |
| Disabling pain                                           | 2 |

| Minor complications                                      |          |
|----------------------------------------------------------|----------|
| Mild pain, skin hyperemia, numbness, mild surgical wound| 162      |
| infection, mild ulceration                               |          |

**Total** 193
In the present study, a lower complication rate of 22.8% was observed with the Sophono implant, and the most frequent complication described was a minor one, related to pain or pressure around the external unit, with the symptoms being relieved by decreasing magnet intensity, as previously reported by Shin (2016). However, some studies, such as the one by Marsella (2014), also report the persistence of this symptom, even with a decrease in the intensity of the magnet, making it unfeasible for the patient to use the device due to pain, which constitutes a major complication.

Regarding the occurrence and treatment of major complications, in the present review, a complication rate of 5.7% was observed for BoneBridge, which is in agreement with literature studies, such as that by Brkic (2020), in which the rate of major complications with the use of BoneBridge was 9.4% (6/64), including 5 explantations and 1 reimplantation. Similar results were also found in the study by Seiwert (2021), in which the major complication rate was 6.2%.

The overall rate of complications in the present series was 21.3%, which compares favorably to the high rates of complications associated with percutaneous devices, which according to the literature can range from 8 to 59%. Transcutaneous devices generally show a significant reduction in patient injuries when compared with percutaneous models.

The present study has some limitations. Being a systematic review, it is limited by the individual methodology of the articles included, since there was no restriction regarding the study design of the articles included, which was reflected in the heterogeneity of the studies regarding the follow-up period, the audiological measures, and the reports of complications. There is no validated scale for complications resulting from transcutaneous devices. Therefore, it is difficult to define which minor complications, such as erythema or pain at the implant site, are clinically significant, and this category is presumed by the authors in cases in which the treatment was conservative, similarly to other published works. It is worth mentioning that the complication rates in the present work may be overestimated, due to the fact that the selected studies necessarily addressed complications—whether major or minor—and those studies that did not mention complications in their text were excluded.

**Final Comments**

Hearing implants offer a viable hearing alternative compared with percutaneous devices, and represent an alternative hearing resource for the patient. Although there is a frequency attenuation through soft tissue and its thickness, lower rates of postoperative complications and the aesthetics of a skin hearing implant make it an appealing option. Complications generally tend to be mild and managed clinically. However, major complications can occur, and it is essential that doctors are attentive to this possibility, especially in selected patients. Hence the importance of a well-reasoned, judicious indication, with a rigorous selection of patients.

**Conflict of Interests**

The authors have no conflict of interests to declare.

**References**

1. Berger KW. Early bone conduction hearing aid devices. Arch Otolaryngol 1976;102(05):315–318
2. Perciaccante A, Coralli A, Bauman NG. Beethoven: His hearing loss and his hearing aids. Otol Neurotol 2020;41(09):1305–1308
3. Kara A, Iseri M, Durgut M, Topdag M, Ozturk M. Comparing audiological test results obtained from a sound processor attached to a Softband with direct and magnetic passive bone conduction hearing implant systems. Eur Arch Otorhinolaryngol 2016;273(12):4193–4198
4. Nguix T, Tang IP. Bonebridge transcutaneous bone conduction implant in children with congenital aural atresia: surgical and audiological outcomes. J Laryngol Otol 2018;132(08):693–697
5. Reinfeldt S, Håkansson B, Taghavi H, Eeg-Olofsson M. New developments in bone-conduction hearing implants: a review. Med Devices (Auckl) 2015;8:79–93
6. Dumper J, Hodgetts B, Liu R, Brandner N. Indications for bone-anchored hearing AIDS: a functional outcomes study. J Otolaryngol Head Neck Surg 2009;38(01):96–105
7. Bento RF, Kiesewetter A, Ikari LS, Brito R. Bone-anchored hearing aid (BAHA): indications, functional results, and comparison with reconstructive surgery of the ear. Int Arch Otorhinolaryngol 2012;16(03):400–405
8. Lavilla Martin de Valmaseda MJ, Cavalle Garrido L, Huarte Irujo A, et al. Clinical guideline on bone conduction implants. Acta Otorrinolaringol Esp 2019;70(02):105–111
9. Ellsperman SE, Nairn EM, Stucken EZ. Review of bone conduction hearing devices. Audiology Research. Audiology Res 2021;11(02):207–219
10. Siau RT, Dhillon B, Siau D, Green KM. Bone-anchored hearing aids in conductive and mixed hearing losses: why do patients reject them? Eur Arch Otorhinolaryngol 2016;273(10):3117–3122
11. Dun CAJ, Faber HT, de Wolf MJF, Mylanus EA, Cremers CW, Hol MK. Assessment of more than 1,000 implanted percutaneous bone conduction devices: skin reactions and implant survival. Otol Neurotol 2012;33(02):192–198
12. Kiringoda R, Lustig LR. A meta-analysis of the complications associated with osseointegrated hearing aids. Otol Neurotol 2013;34(05):790–794
13. den Besten CA, Nelissen RC, Peer PG, et al. A retrospective cohort study on the influence of comorbidity on soft tissue reactions, revision surgery, and implant loss in bone-anchored hearing implants. Otol Neurotol 2015;36(05):812–818
14. Mohamad S, Khan I, Hey SY, Hussain SS. A systematic review on skin complications of bone-anchored hearing aids in relation to surgical techniques. Eur Arch Otorhinolaryngol 2016;273(03):559–565
15. Marfatia H, Shah K, Shelke S, Krishnan K. Baha Attract: our experience. Indian J Otolaryngol Head Neck Surg 2017;69(04):544–548
16. Sharma S, Bulstrode N, Marshall A. Implantation and positioning of a transcutaneous magnetic bone conduction hearing system for children with microtia in preparation for auricular reconstruction. Clin Otolaryngol 2018;43(02):779–781
17. Hol MKS, Nelissen RC, Agterberg MJH, Cremers CW, Snik AF. Comparison between a new implantable transcutaneous bone conductor and percutaneous bone-conduction hearing implant. Otol Neurotol 2013;34(06):1071–1075
18. Iseri M, Orhan KS, Tencer U, et al. Transcutaneous bone-anchored hearing aids versus percutaneous ones. Otol Neurotol 2015;36(05):849–853
Brkic FF, Riss D, Scheuba K, et al. Medical, technical and audiological outcomes of hearing rehabilitation with the bonebridge transcutaneous bone-conduction implant: A single-center experience. J Clin Med 2019;8(10):1614

O’Niel MB, Runge CL, Friedland DR, Kerschner JE. Patient outcomes in magnet based implantable auditory assist devices. JAMA Otolaryngol Head Neck Surg 2014;140(06):513–520

Zernotti ME, Chiaraviglio MM, Mauricio SB, Tabernero PA, Zernotti M, Di Gregorio MF. Audiological outcomes in patients with congenital aural atresia implanted with transcutaneous active bone conduction hearing implant. Int J Pediatr Otorhinolaryngol 2019;119:54–58

Zernotti ME, Di Gregorio MF, Galeazzi P, Tabernero P. Comparative outcomes of active and passive hearing devices by transcutaneous bone conduction. Acta Otolaryngol 2016;136(06):556–558

Kruyt IJ, Monksfield P, Skarzyński PH, et al. Results of a 2-year prospective multicenter study evaluating long-term audiological and clinical outcomes of a transcutaneous implant for bone conduction hearing. Otol Neurotol 2020;41(07):901–911

Gawęcki W, Balcerowia K, Kalinowicz E, Wróbel M. Evaluation of surgery and surgical results of Baha® Attract system implantations - single centre experience of hundred twenty five cases. Rev Bras Otorrinolaringol (Engl Ed) 2019;85(05):597–602

Shin JW, Kim SH, Choi JY, et al. Surgical and audiologic comparison between sophono and bone-anchored hearing aids implantation. Clin Exp Otorhinolaryngol 2016;9(01):21–26

Marsella P, Scorpecci A, Vallarino MV, Di Fiore S, Pacifico C. Sophono in pediatric patients: The experience of an Italian tertiary care center. Otolaryngol Head Neck Surg 2014;151(02):328–332

Seiwert I, Fröhlich I, Schilde S, Götz G, Plontke SK, Rahne T. Clinical and functional results after implantation of the bonebridge, a semi-implantable, active transcutaneous bone conduction device, in children and adults. Eur Arch Otorhinolaryngol 2022 Jan;279(01):101–113

Hobson JC, Roper AJ, Andrew R, Rothera MF, Hill P, Green KM. Complications of bone-anchored hearing aid implantation. J Laryngol Otol 2010;124(02):132–136

Goycoolea M, Ribalta G, Tocornal F, et al. Clinical performance of the Osia™ system, a new active osseointegrated implant system. Results from a prospective clinical investigation. Acta Otolaryngol 2020;140(03):212–219

Sprinzl GM, Wolf-Magele A. The Bonebridge Bone Conduction Hearing Implant: indication criteria, surgery and a systematic review of the literature. Clin Otolaryngol 2016;41(02):131–143

Lin J, Chen S, Zhang H, et al. Application of Implantable Hearing Aids and Bone Conduction Implant System in patients with bilateral congenital deformation of the external and middle ear. Int J Pediatr Otorhinolaryngol 2019;119:89–95

Mylanus EAM, Hua H, Wigren S, et al. Multicenter clinical investigation of a new active osseointegrated steady-state implant system. Otol Neurotol 2020;41(09):1249–1257